Literature DB >> 11331473

Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.

J F Pingpank1, J P Hoffman, E A Ross, H S Cooper, N J Meropol, G Freedman, W H Pinover, T E LeVoyer, A R Sasson, B L Eisenberg.   

Abstract

We examined the effect of preoperative chemoradiotherapy on the ability to obtain pathologically negative resection margins in patients undergoing pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas. Between 1987 and 2000, 100 patients underwent Whipple resection with curative intent for primary adenocarcinoma of the head of the pancreas. Pathologic assessment of six margins (proximal and distal superior mesenteric artery, proximal and distal superior mesenteric vein, pancreas, retroperitoneum, common bile duct, and hepatic artery) was undertaken by either frozen section (pancreas and common duct) or permanent section. A margin was considered positive if tumor was present less than 1 mm from the inked specimen. Margins noted to be positive on frozen section were resected whenever possible. Of the 100 patients treated, 47 (47%) underwent postoperative radiation and chemotherapy (group I) and 53 (53%) received preoperative chemoradiotherapy (group II) with either 5-fluorouracil (32 patients) or gemcitabine (21 patients). Patient demographics and operative parameters were similar in the two groups, with the exception of preoperative tumor size (CT scan), which was greater in group II (P < 0.001), and number of previous operations, which was greater in group II (P < 0.0001). Statistical analysis of the number of negative surgical margins clear of tumor was performed using Fisher's exact test. All patients (100%) had six margins assessed for microscopic involvement with tumor. In the preoperative therapy group, 5 (7.5%) of 53 patients had more than one positive margin, whereas 21 (44.7%) of 47 patients without preoperative therapy had more than one margin with disease extension (P < 0.001). Additionally, only 11 (25.6%) of the 47 patients without preoperative therapy had six negative margins vs. 27 (50.9%) of 53 in the group receiving preoperative therapy (P = 0.013). Survival analysis reveals a significant increase in survival in margin-negative patients (P = 0.02). Similarly, a strong trend toward improved disease-free and overall survival is seen in patients with a single positive margin vs. multiple margins. Overall, we find a negative impact on survival with an increasing number of positive margins (P = 0.025, hazard ratio 1.3). When stratified for individual margin status, survival was decreased in patients with positive superior mesenteric artery (P = 0.06) and vein (P = 0.04) margins. However, this has not yet resulted in a significant increase in disease-free or overall survival for patients receiving preoperative therapy (P = 0.07).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331473     DOI: 10.1016/s1091-255x(01)80023-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

Review 1.  Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.

Authors:  C Chao; J P Hoffman; E A Ross; M H Torosian; B L Eisenberg
Journal:  Am Surg       Date:  2000-04       Impact factor: 0.688

2.  Survival in 1001 patients with carcinoma of the pancreas.

Authors:  M M Connolly; P J Dawson; F Michelassi; A R Moossa; F Lowenstein
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

3.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

4.  Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas.

Authors:  G Benassai; M Mastrorilli; G Quarto; A Cappiello; U Giani; P Forestieri; F Mazzeo
Journal:  J Surg Oncol       Date:  2000-04       Impact factor: 3.454

Review 5.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Authors:  F R Spitz; J L Abbruzzese; J E Lee; P W Pisters; A M Lowy; C J Fenoglio; K R Cleary; N A Janjan; M S Goswitz; T A Rich; D B Evans
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.

Authors:  C J Yeo; J L Cameron; T A Sohn; K D Lillemoe; H A Pitt; M A Talamini; R H Hruban; S E Ord; P K Sauter; J Coleman; M L Zahurak; L B Grochow; R A Abrams
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

7.  Adjuvant therapy of resected adenocarcinoma of the pancreas.

Authors:  R Whittington; M P Bryer; D G Haller; L J Solin; E F Rosato
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-10       Impact factor: 7.038

8.  Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

Authors:  C G Willett; K Lewandrowski; A L Warshaw; J Efird; C C Compton
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

9.  A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group.

Authors: 
Journal:  Ann Surg       Date:  1979-02       Impact factor: 12.969

10.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more
  45 in total

Review 1.  The role of radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

2.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

3.  A novel approach to the intraoperative assessment of the uncinate margin of the pancreaticoduodenectomy specimen.

Authors:  Mahmoud A Khalifa; Vlad Maksymov; Corwyn H Rowsell; Sherif Hanna
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

4.  Current status of adjuvant therapy for pancreatic cancer.

Authors:  Matthew H G Katz; Jason B Fleming; Jeffrey E Lee; Peter W T Pisters
Journal:  Oncologist       Date:  2010-11-02

5.  Redefining resection margin status in pancreatic cancer.

Authors:  Caroline S Verbeke; Krishna V Menon
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

6.  Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).

Authors:  Krishna V Menon; Dhanwant Gomez; Andrew M Smith; Alan Anthoney; Caroline S Verbeke
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

Review 7.  Surgical treatment for advanced pancreatic cancer.

Authors:  Hyung Jun Kwon; Sang Geol Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-08-31

8.  Impact of preoperative therapy on patterns of recurrence in pancreatic cancer.

Authors:  Pavlos Papavasiliou; John P Hoffman; Steven J Cohen; Joshua E Meyer; James C Watson; Yun Shin Chun
Journal:  HPB (Oxford)       Date:  2013-02-20       Impact factor: 3.647

9.  Pancreaticoduodenectomy with combined superior mesenteric vein resection without reconstruction is possible: A case report and review of the literature.

Authors:  Lionel Jouffret; Theophile Guilbaud; Olivier Turrini; Jean-Robert Delpero
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

10.  Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.

Authors:  Matthew H G Katz; Gauri R Varadhachary; Jason B Fleming; Robert A Wolff; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Charlotte C Sun; Huamin Wang; Christopher H Crane; Jeffrey H Lee; Eric P Tamm; James L Abbruzzese; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2010-02-17       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.